William Blair Reiterates Outperform Rating for Merus (NASDAQ:MRUS)

William Blair restated their outperform rating on shares of Merus (NASDAQ:MRUS) in a research report released on Monday, RTT News reports.

Several other brokerages also recently weighed in on MRUS. Truist Financial started coverage on shares of Merus in a report on Thursday, March 28th. They set a buy rating and a $69.00 price target on the stock. Stifel Nicolaus lifted their price objective on shares of Merus from $40.00 to $65.00 and gave the company a buy rating in a research report on Thursday, February 29th. HC Wainwright lifted their price objective on shares of Merus from $48.00 to $65.00 and gave the company a buy rating in a research report on Thursday, February 29th. Needham & Company LLC reiterated a buy rating and set a $66.00 price objective on shares of Merus in a research report on Thursday, April 11th. Finally, BMO Capital Markets lifted their price objective on shares of Merus from $49.00 to $58.00 and gave the company an outperform rating in a research report on Thursday, February 29th. One research analyst has rated the stock with a sell rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, Merus presently has a consensus rating of Moderate Buy and an average target price of $56.33.

Merus Stock Up 7.1 %

Shares of NASDAQ:MRUS opened at $44.93 on Monday. Merus has a 1-year low of $18.21 and a 1-year high of $52.03. The firm’s 50 day simple moving average is $45.03 and its two-hundred day simple moving average is $33.58.

Merus (NASDAQ:MRUS) last issued its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.38). Merus had a negative net margin of 352.56% and a negative return on equity of 50.61%. The firm had revenue of $8.94 million for the quarter, compared to analysts’ expectations of $10.43 million. On average, sell-side analysts anticipate that Merus will post -3.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Merus

Several large investors have recently bought and sold shares of MRUS. BluePath Capital Management LLC purchased a new position in Merus during the third quarter worth $33,000. Quadrant Capital Group LLC boosted its stake in Merus by 37.7% during the fourth quarter. Quadrant Capital Group LLC now owns 1,253 shares of the biotechnology company’s stock worth $34,000 after buying an additional 343 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in Merus by 142.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,477 shares of the biotechnology company’s stock worth $35,000 after buying an additional 867 shares during the period. Tower Research Capital LLC TRC boosted its stake in Merus by 64.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,120 shares of the biotechnology company’s stock worth $58,000 after buying an additional 828 shares during the period. Finally, Allspring Global Investments Holdings LLC purchased a new position in Merus during the first quarter worth $72,000. Institutional investors own 96.14% of the company’s stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.